Tresiba (insulin degludec) and Lantus (insulin glargine) are Food and Drug Administration (FDA)-approved synthetic insulins for glycemic control (blood sugar levels) in people with type 1 or type ...

Now, providers will have to determine which other insulin brand is preferred during pregnancy. Tresiba (insulin degludec), a longer-acting insulin, has been shown to be safe and effective in ...

The approval covers all 27 European Union member states. Tresiba (insulin degludec) is a once-daily new-generation based insulin analogue with an ultra-long duration of action. Ryzodeg (insulin ...

Novo Nordisk is applying for an expanded US label for its long-acting insulin Tresiba, hoping to gain an upper hand on Sanofi's older rival Lantus. Its data submitted to the FDA shows that ...

The pipeline includes treatments for diabetes, obesity and haemophilia. Its most keenly-anticipated new insulin product is Tresiba (degludec), which received a boost after the US drugs regulator ...